How International Standards for Molecular Biomarker Testing in Lung Cancer Have Influenced Which Tests are Routinely PerformedVideo Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library
Drs. Roy Herbst and David Rimm discuss the 50-gene panel that has become an ISLC-mandated standard for all patients with lung cancer; however, the components of cancer biomarker testing panels must be fluid and respond to new developments in the field as reported in the literature and/or at international cancer meetings, with adoption of the test predicated on standardization and the perceived value of the test.
Dr. Boccia addresses the problem of unclear diagnoses affecting approximately 15% of newly diagnosed patients with metastatic disease each year and the importance of an accurate diagnosis of tumor type in selecting the proper site-specific therapies.
Dr. Gary Palmer explains how Foundation Medicine is working to improve cancer therapies and personalized medicine on a molecular level.